|
Geometric mean plasma levels3 of E2, FSH, P4 and SHBG according to use of HRT among postmenopausal women |
|||||
| E2 dosage category |
E2¤ nmol/L |
FSH¶ IU/L |
P4 nmol/L |
SHBG‡ nmol/L |
|
| n |
95% CI |
95% CI |
95% CI |
95% CI |
|
|
|
|||||
| No HRT |
2651 |
0.07 (0.06–0.07) |
69.6 (65.9–73.5) |
0,82 (0.76–0.89) |
42.4 (40.2–44.8) |
| HRT |
|||||
| HRT without E2 |
20 |
0.07 (0.06–0.08) |
53.4 (44.0–64.9) |
0,65 (0.49–0.87) |
34.9 (28.7–42.4) |
| Vaginal E2 |
5 |
0.07 (0.05–0.10) |
70.4 (47.8–104) |
0,99 (0.56–1.76) |
33.4 (22.6–49.4) |
| Patches |
9 |
0.15 (0.12–0.19) |
36.4 (27.3–48.5) |
1,05 (0.68–1.61) |
47.0 (35.1–62.8) |
| Oral 1 mg |
232 |
0.23 (0.20–0.27) |
36.9 (30.6–44.6) |
0,46 (0.35–0.60) |
52.1 (43.4–62.5) |
| Oral 2 mg |
9 |
0.29 (0.22–0.38) |
18.7 (14.1–25.0) |
0,79 (0.51–1.21) |
62.5 (46.8–83.6) |
| ANCOVA3 |
p < 0.01 |
p < 0.01 |
p < 0.01 |
p < 0.01 |
|
|
1FSH: n = 252 2 FSH: n = 21 3 Covariates included in addition to age: ‡ BMI, ¶ BMI and alcohol, ¤ BMI and BMI*age interaction term. Parity did not contribute significantly to the model for any of the analyses, and was omitted. | |||||
Waaseth et al. BMC Women's Health 2008 8:1 doi:10.1186/1472-6874-8-1 |
|||||